Disbiose associada à Doenças Metabólicas: OBESIDADE
Palavras-chave:
Microbiota gastrointestinal. Microbioma gastrointestinal. Disbiose. Ganho de peso. Obesidade.Resumo
As alterações na microbiota intestinal, chamada de disbiose intestinal, tem sido incluída entre os inúmeros fatores propostos como possíveis causas para a obesidade. O papel da microbiota intestinal tem sido apoiado por evidências preliminares que mostram uma relação entre a alteração da composição e concentração de bactérias residentes do trato intestinal e o potencial para ganho ponderal de gordura entre os pacientes. Ainda que a composição da microbiota intestinal apresente uma pequena variação interindividual em condições saudáveis, esse padrão não é mantido em intestinos de indivíduos obesos, onde encontra-se uma grande quantidade de genes microbianos alterados. Nesse contexto, tem sido ainda propostos vários mecanismos associados à disbiose como causadores de distúrbios metabólicos, entre eles, a obesidade. Portanto, o conhecimento de que as bactérias possam interferir de forma negativa sobre os processos bioquímicos na composição calórica e nutricional do organismo, e de como como elas alteram o fenótipo do indivíduo é uma alternativa para trazer respostas para o tratamento de varias doenças a fim de evitar processos disbióticos no trato gastrointestinal.
Referências
Lynch SV, Pedersen O. The Human Intestinal Microbiome in Health and Disease. New England Journal of Medicine. 2016; 375(24):2369-2379.
Mondot S, de Wouters T, Dore J, Lepage P. The human gut microbiome and its dysfunc-tions. Digestive Diseases. 2013; 31(3-4):278-285.
Vigilância de Fatores de Risco e Proteção para Doenças Crônicas por Inquérito Telefônico (VIGITEL). Estimativas sobre frequência e distribuição sócio-demográfica de fatores de risco e proteção para doenças crônicas nas capitais dos 26 estados brasileiros e no distrito federal em 2016. Brasília: Ministério da Saúde, 2017.
The NS, Suchindran C, North KE, Popkin BM, Gordon-Larsen P. Association of adoles-cent obesity with risk of severe obesity in adulthood. JAMA. 2010; 304(18):2042-2047.
Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM: monthly journal of the Association of Physicians. 2007; 100 (7):395-404.
Lloyd-Price J, Mahurkar A, Rahnavard G, Crabtree J, Orvis J, Hall AB, et al. Strains, functions and dynamics in the expanded Human Microbiome Project. Nature. 2017; 550(7674): 61-66.
Ferrer M, Ruiz A, Lanza F, Haange SB, Oberbach A, Till H, et al. Microbiota from the distal guts of lean and obese adolescents exhibit partial functional redundancy besides clear differences in community structure. Environmental Microbiology. 2013; 15(1):211-226.
Cani PD. Gut microbiota and obesity: lessons from the microbiome. Rev. Briefings in Functional Genomics. 2013; 12(4):381-387.
Hjorth MF, Blædel T, Bendtsen LQ, Lorenzen JK, Holm JB, Kiilerich P et al. Prevotella-to-Bacteroides ratio predicts body weight and fat loss success on 24-week diets varying in macronutrient composition and dietary fiber: results from a post-hoc analysis. International Journal of Obesity. 2019; 43(1):149-157.
Angelakis E, Armougom F, Million M, Raoult D. The relationship between gut microbiota and weight gain in humans. Future Microbiology. 2012; 7(1):91-109.
Harris K, Kassis A, Major G, Chou CJ. Is the gut microbiota anew factor contributing to obesity and its metabolic disorders? Journal of Obesity. 2012; 2012:879151.
Yan H, Diao H, Xiao Y, Li W, Yu B, He J, et al. Gut microbiota can transfer fiber charac-teristics and lipid metabolic profiles of skeletal muscle from pigs to germ-free mice. Scien-tific Reports. 2016; 6(1):31786.
Rabot S, Membrez M, Blancher F, Berger B, Moine D, Krause L, et al. High fat diet drives obesity regardless the composition of gut microbiota in mice. Scientific Reports. 2016; 6:32484.
Fox CS, Pencina MJ, D'Agostino RB, Murabito JM, Seely EW, Pearce EN, et al. Rela-tions of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Archives of Internal Medicine. 2008; 168(6):587-592.
Chaput JP, Klingenberg L, Rosenkilde M, Gilbert JA, Tremblay A, Sjödin A. Physical activity plays an important role in body weight regulation. Journal of Obesity. 2011; 2011:360257.
Davenport ER, Sanders JG, Song SJ, Amato KR, Clark AG, Knight R. The human micro-biome in evolution. BMC Biology. 2017; 15(1):127.
Guaraldi F, Salvatori G. Effect of Breast and Formula Feeding on Gut Microbiota Shap-ing in Newborns. Frontiers in Cellular and Infection Microbiology. 2012; 2:94.
Mueller NT, Whyatt R, Hoepner L, Oberfield S, Dominguez-Bello MG, Widen EM, et al. Prenatal exposure to antibiotics, cesarean section and risk of childhood obesity. Interna-tional Journal of Obesity. 2015; 39(4):665-670.
Tun HM, Bridgman SL, Chari R, Field CJ, Guttman DS, Becker AB, et al. Roles of Birth Mode and Infant Gut Microbiota in Intergenerational Transmission of Overweight and Obesity From Mother to Offspring. JAMA Pediatrics. 2018; 172(4):368-377.
Tilg H. Obesity, metabolic syndrome, and microbiota: multiple interactions. Journal of Clinical Gastroenterology. 2010; 44 Suppl 1:S16-18.
David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014; 23(505):559-563.
Mehrpouya-Bahrami P, Chitrala KN, Ganewatta MS, Tang C, Murphy AE, Enos RT, et al. Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity. Scientific Reports. 2017; 7(1):15645.
Rodriguez-Nunez I, Caluag T, Kirby K, Rudick CN, Dziarski R, Gupta D. Nod2 and Nod2-regulated microbiota protect BALB/c mice from diet-induced obesity and metabolic dysfunction. Scientific Reports. 2017; 7(1):548.
Lian H, An Y, Hao F, Wang Y, Tang H. Correlations of Fecal Metabonomic and Microbi-omic Changes Induced by High-fat Diet in the Pre-Obesity State. Scientific Reports. 2016; 6:21618.
Jones ML, Martoni CJ, Ganopolsky JG, Prakash S. The human microbiome and bile acid metabolism: dysbiosis, dysmetabolism, disease and intervention. Expert Opinion on Biol-ogy Therapy. 2014; 14(4):467-482.
Nishitsuji K, Xiao J, Nagatomo R, Umemoto H, Morimoto Y, Akatsu H, et al. Analysis of the gut microbiome and plasma short-chain fatty acid profiles in a spontaneous mouse model of metabolic syndrome. Scientific Reports. 2017; 7(1):15876.
Rizkallah MR, Saad R, Aziz RK. The Human Microbiome Project, Personalized Medicine and the Birth of Pharmacomicrobiomics. Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics). 2010; 8(3):182-193.
Kanai T, Matsuoka K, Naganuma M, Hayashi A, Hisamatsu T. Diet, microbiota, and in-flammatory bowel disease: lessons from Japanese foods. The Korean Journal of Internal Medicine. 2014; 29(4):409-415.
Rodrigues L dos SV. RELAÇÃO ENTRE MICROBIOTA INTESTINAL E OBESIDADE: terapêutica nutricional através do uso de probióticos. 34f. Monografia (Graduação)- Faculdade de Ciências da Educação e Saúde, Centro Universitário de Brasília (UNICEUB). Brasília. 2016. Disponível em: <https://repositorio.uniceub.br/jspui/handle/235/9243>. Acesso em 24 de agosto de 2019.
Kotzampassi K, Giamarellos-Bourboulis EJ, Stavrou G. Obesity as a Consequence of Gut Bacteria and Diet Interactions. Rev. ISRN Obesity. 2014; 2014: 651895.
Calleya RNA. A ingestão de probióticos e prebióticos na prevenção e tratamento de doenças intestinais: uma revisão integrativa na área da nutrição. Guarapuava-Trabalho de conclusão de curso-Universidade Estadual do Centro-Oeste (UNICENTRO)- Departamento de Nutrição. 2010. Disponível em: <https://www.unicentro.br/graduacao/denut/documentos/tcc/2010/TCC%2032-2010%20(ROSA%20NORIKO%20ARAKI%20CALLEYA).pdf>. Acesso em 24 de agosto de 2019.
Cani PD, Delzenne NM. The gut microbiome as therapeutic target. Pharmacology e Thera-peutics. Rev. Pharmacology & Therapeutics. 2011; 130(2):202-212.
Ganc AJ, Ganc RL, Reimão SM, Junior AF, Pasternak J. Transplante de microbiota fecal por enteroscopia alta para o tratamento da diarreia causada por Clostridium difficile. Einsten. 2015; 13(2):338-339. Disponível em: <http://www.scielo.br/pdf/eins/v13n2/pt_1679-4508-eins-13-2-0338.pdf>. Acesso em 11 setembro de 2019.
Jalanka J, Hillamaa A, Satokari R, Mattila E, Anttila VJ, Arkkila P. The long-term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection. Alimentary Pharmacology & Thera-peutics. 2018; 47(3):371-379.
Johnsen PH, Hilpusch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syn-drome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. The Lancet Gastroenterology and Hepatology. 2018; 3(1):17-24.
